Valeant Pharmaceuticals International

Type: Company
Name: Valeant Pharmaceuticals International
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

Valeant invests in Vietnam’s pharmaceutical industry

Quebec-headquartered Valeant has successfully established a foothold in Vietnam after the Canada's largest drug company completed its joint venture with Euvipharm for over $20 million in late 2013.Valeant CEO Mike Pearson on a country briefing visit to ... [Published Vietnamese Investment Review - Apr 19 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 2 reports

Valeant Pharmac. (VRX) Trading Near $116.06 Support Level

Valeant Pharmac. (http://www.marketintelligencecenter.com/symbol/VRX"VRX) presents a trading opportunity that offers a 9.74% return in just 93 days.A covered call on Valeant Pharmac. at the $120.00 level expiring on Jul. '14 offers an assigned return ... [Published Individual.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Abbott Labs Earnings: Still Marking Time

Like many other large med-tech companies, Abbott Labs ( NYSE: ABT     ) remains an exercise in frustration right now. There are pressures throughout most of the company's business lines, with only the diagnostics business really showing much growth. ... [Published Motley Fool Discussion Boards - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Shares of Valeant Pharmaceuticals International Receive a Boost, Up 1.9%

One of today's notable stocks on the rise is Valeant Pharmaceuticals International (NYSE:VRX), up 1.9% to $122.44. The S&P is trading higher by 0.6% to 1,854 and the Dow is trading 0.7% higher to 16,369. ... [Published Individual.com - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

Valeant Pharmaceuticals International Down 14.8% Since SmarTrend Downtrend Call (VRX)

Written on Tue, 04/15/2014 - 11:19amBy Shiri GuptaSmarTrend identified a Downtrend for Valeant Pharmaceuticals International ( NYSE:VRX ) on March 7th, 2014 at $138.23. In approximately 1 month, Valeant Pharmaceuticals International has returned 14.82% ... [Published Comtex SmarTrend - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Global Dermatophytic Onychomycosis Therapeutics Market Report

DUBLIN , Apr. 10, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/pnf52x/global) has announced the addition of the " " report to their offering.(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )The analysts ... [Published Asian Hospital & Healthcare Management - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Is This the Time to Buy Pharma Stocks?

In this edition of 's "Ask a Fool" series, Motley Fool One analyst Jason Moser and Motley Fool Stock Advisor analyst Brendan Mathews take a question from a reader who asks: "Many pharma companies went down 30 to 40%. Is it good time to buy pharma stocks? ... [Published Motley Fool - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 3 reports

Next Takeover Rumor

Supposedly both Novartis and Shire may be leading candidates to buy Belgium-based eye company ThromboGenics. Morgan Stanley is said to be leading the way in discussions towards this end. Also rumored to be on the fringes are Valeant Pharmaceuticals,. ... [Published BioPortfolio - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Dysport(r), a Leading Cosmetic Injectable in Europe, Now Available in Canada

04/14 10:40 CDT TORONTO, April 14, 2014Only Botulinum Toxin in Canada with an Onset as Early as 24 HoursTORONTO, April 14, 2014 /CNW/ - Medicis Canada, a division of Valeant Canada, is officially launching Dysport(r) for use in aesthetic medicine in ... [Published Finwin - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Dysport®, a Leading Cosmetic Injectable in Europe, Now Available in Canada

Only Botulinum Toxin in Canada with an Onset as Early as 24 HoursTORONTO, April 14, 2014 /CNW/ - Medicis Canada, a division of Valeant Canada, is officially launching Dysport® for use in aesthetic medicine in Canada. One of Europe's leading cosmetic ... [Published TickerTech.com - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Valeant Pharmaceuticals Intl Given New $165.00 Price Target at BMO Capital Markets (BVF)

Tweet[embedded content]Valeant Pharmaceuticals Intl (NYSE:BVF) had its target price cut by BMO Capital Markets from $171.00 to $165.00 in a report issued on Friday, AnalystRatings.NET reports.BMO Capital Markets has also updated their ratings on a number ... [Published Zolmax News - Apr 14 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 97 reports

Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes

/PRNewswire/ --On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors ... [Published Nasdaq - Mar 21 2014]

Quotes

"Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" Now Available at Fast Market Research
Valeant Pharmac. (http://www.marketintelligencecenter.com/symbol/VRX "VRX) presents a trading opportunity that offers a 9.74% return in just 93 days."
...a Fool" series, Motley Fool One analyst Jason Moser and Motley Fool Stock Advisor analyst Brendan Mathews take a question from a reader who asks: "Many pharma companies went down 30 to 40%. Is it good time to buy pharma stocks? Can you give some good picks on pharma?"
...Dysport(r) to Canada and to offer a product that allows patients to look their very best," says Gene Smith, Product Manager, Medicis Canada. "We are confident Canadians who use it will make it their first choice for cosmetic injectables."

More Content

All (522) | News (402) | Reports (0) | Blogs (86) | Audio/Video (0) | Fact Sheets (2) | Press Releases (28)
sort by: Date | Relevance
Valeant invests in Vietnam’s pharmaceutical ind... [Published Vietnamese Investment Review - Apr 19 2014]
Royalty Financing Partnering Terms and Agreemen... [Published SBWire - Apr 18 2014]
"Option and Evaluation Partnering Terms and Agr... [Published SBWire - Apr 18 2014]
The 'Boring' Fund That Keeps Crushing The Market [Published StreetAuthority - Apr 18 2014]
Asset Purchase Terms and Agreements in Pharma, ... [Published SBWire - Apr 18 2014]
Recent Study: Personalized Medicine Partnering ... [Published Digital Journal - Apr 18 2014]
Valeant Pharmac. (VRX) Trading Near $116.06 Sup... [Published Individual.com - Apr 17 2014]
New Report Available: Companion Diagnostics Par... [Published SBWire - Apr 17 2014]
Clinical Stage Partnering Terms and Agreements ... [Published SBWire - Apr 17 2014]
Canadian Stocks Recover From Weak Start -- Cana... [Published RTTNews.com - Apr 17 2014]
Valeant Pharmac. (VRX) Trading Near $116.06 Sup... [Published MarketIntelligenceCenter.com - Apr 17 2014]
Abbott Labs Earnings: Still Marking Time [Published Motley Fool Discussion Boards - Apr 16 2014]
Shares of Valeant Pharmaceuticals International... [Published Individual.com - Apr 16 2014]
Valeant Pharmac. (VRX) Showing Bearish Technica... [Published MarketIntelligenceCenter.com - Apr 16 2014]
Hottest Healthcare Stocks Now – CNMD EXAS ACAD ... [Published InvestorPlace.com - Apr 15 2014]
An overview of phototherapy for psoriasis [Published The Clinical Advisor - Apr 15 2014]
Valeant Pharmaceuticals International Down 14.8... [Published Comtex SmarTrend - Apr 15 2014]
Valeant Pharmaceuticals International Down 14.8... [Published Individual.com - Apr 15 2014]
Global Dermatophytic Onychomycosis Therapeutics... [Published Asian Hospital & Healthcare Management - Apr 15 2014]
Albany Molecular Aspires To Grow Revenue Five-F... [Published Seeking Alpha - Apr 15 2014]
Is This the Time to Buy Pharma Stocks? [Published Motley Fool - Apr 15 2014]
Potential Valeant Pharmac. (VRX) Trade Has 10.3... [Published MarketIntelligenceCenter.com - Apr 15 2014]
Next Takeover Rumor [Published BioPortfolio - Apr 14 2014]
ThromboGenics is picking between billion-dollar... [Published FierceBiotech - Apr 14 2014]
Next Takeover Rumor [Published The Big Red Biotech Blog - Apr 14 2014]
Dysport(r), a Leading Cosmetic Injectable in Eu... [Published Finwin - Apr 14 2014]
Novartis to Shire Said to Weigh Bids for Drugma... [Published Washington Post - Apr 14 2014]
Dysport®, a Leading Cosmetic Injectable in Eur... [Published TickerTech.com - Apr 14 2014]
Valeant Pharmac. (VRX) Showing Resistance Near ... [Published MarketIntelligenceCenter.com - Apr 14 2014]
Valeant Pharmaceuticals Intl Given New $165.00 ... [Published Zolmax News - Apr 14 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Valeant Pharmac. (VRX) Trading Near $116.06 Sup... [Published MarketIntelligenceCenter.com - Apr 17 2014]
Valeant Pharmac. (VRX) presents a trading opportunity that offers a 9.74% return in just 93 days.A covered call on Valeant Pharmac. at the $120.00 level expiring on Jul. '14 offers an assigned return rate of 9.74% or 38.22% annualized. This trade offers ...
Valeant Pharmac. (VRX) Showing Bearish Technica... [Published MarketIntelligenceCenter.com - Apr 16 2014]
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center  are highlighting two trades on Valeant Pharmac. (VRX) today after it closed at $120.12 on Tuesday. For more conservative investors, ...
Potential Valeant Pharmac. (VRX) Trade Has 10.3... [Published MarketIntelligenceCenter.com - Apr 15 2014]
MarketIntelligenceCenter.com's patented algorithms have identified an attractive covered-call trade on Valeant Pharmac. (VRX). Look at the Jul. '14 $115.00 covered call for a net debit in the $104.89 area. This trade has a duration of 95 days. The break-even ...
Next Takeover Rumor [Published The Big Red Biotech Blog - Apr 14 2014]
Supposedly both Novartis and Shire may be leading candidates to buy Belgium-based eye company ThromboGenics. Morgan Stanley is said to be leading the way in discussions towards this end. Also rumored to be on the fringes are Valeant Pharmaceuticals, Regeneron ...
Valeant Pharmac. (VRX) Showing Resistance Near ... [Published MarketIntelligenceCenter.com - Apr 14 2014]
After Friday’s trading in Valeant Pharmac. (VRX) MarketIntelligenceCenter.com's patented algorithms uncovered a trade that offers a 9.95% return or 37.84% on an annualized basis (for comparison purposes only), while providing 11.95% downside protection. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Health Care Stocks Technical Coverage -- Resear... [Published Financial Services - Apr 09 2014]
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
Reviewing the Top Health Care Equities -- Resea... [Published Financial Services - Mar 21 2014]
Valeant Pharmaceuticals Reports Fourth Quarter ... [Published Financial Services - Feb 27 2014]
Valeant Pharmaceuticals to Acquire Precision De... [Published Financial Services - Feb 03 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.